Philippine FDA approves 10 Senores Pharma products

Regulatory product approvalBusiness Updates View source PDF Explain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹792.00

prior close

₹775.60

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.1%-0.7% vs market

Pharmaceuticals peers, median of 156sector-0.2%-1.5% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.4

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-1.1-0.7-0.2-1.5

Next day

-4.7-3.5-1.2-2.3-2.4

-3.7-1.6-2.1-1.6-2.1

-3.0-2.2-0.9-1.8-1.2

-3.5-1.8-1.8-1.5-2.0

-0.3-1.5+1.2-1.1+0.9

+3.7-1.6+5.3-1.6+5.3

15d

+4.2-2.0+6.2-1.9+6.1

+6.6+0.7+5.9-0.6+7.2

+4.0-3.8+7.7-5.5+9.5

-7.1-9.8+2.7-8.9+1.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Senores Pharmaceuticals has received marketing authorizations from the Philippine FDA for 10 products spanning Cardiovascular, CNS, and Pain management therapy areas. The addressable market for these drugs in the Philippines is estimated at US $23 million. The approvals support the company strategy to expand its footprint in Southeast Asia. Senores currently markets products in over 40 countries with approvals from regulators of more than 10 countries.

Likely market impact

Opens a US $23 million Philippines market across three therapy segments and strengthens Southeast Asia growth strategy.